Researchers to present on topics ranging from
molecular residual disease and immunotherapy to whole-genome
sequencing
BURLINGTON, N.C., April 2,
2024 /PRNewswire/ -- Labcorp (NYSE: LH), a
global leader of innovative and comprehensive laboratory services,
will present abstracts in the areas of immunology, cellular
biology, genomics and liquid biopsy at the Annual Meeting of the
American Association for Cancer Research® (AACR®) in San Diego (April 5-10,
2024).
The depth and breadth of Labcorp's oncology research solidifies
the company's commitment to delivering guideline-based,
biomarker-driven testing solutions, strengthening existing evidence
of clinical utility and supporting the pharmaceutical industry from
discovery to companion diagnostics development through
commercialization to facilitate patient access to novel targeted
therapies.
"Labcorp is advancing cancer care through our pioneering
research in precision oncology and our global collaborations with
pharmaceutical, biotechnology and clinical research partners. Our
robust presence at this year's AACR Annual Meeting is a testament
to our dedication to leading with science, showcasing our
commitment to innovation, and highlighting our role in shaping the
future of personalized medicine," said Shakti Ramkissoon, M.D.,
Ph.D., vice president, medical lead for oncology at Labcorp. "Our
research initiatives are focused on transforming the diagnostic
landscape, enhancing patient care, and fueling a new era of
targeted, effective treatments that will improve health and improve
lives."
Of the 21 abstracts to be presented at the AACR Meeting, 13 were
internal studies by Labcorp researchers and eight were conducted in
collaboration with research partners from premiere academic
institutions and medical centers.
Spotlight Theater
Title: Biomarker solutions for all: Innovative solid
tumor MRD detection and immune profiling solutions for advanced
drug development
Date: Tuesday, April
9
Time: 10:00 a.m. PT
Location: Spotlight Theater A
Oral
Presentations
Abstract #6559: Clinical validity of post-surgery circulating
tumor DNA testing in stage III colon cancer patients treated with
adjuvant chemotherapy: The PROVENC3
study
Date: Tuesday, April 9
Time: 3:10 p.m. - 3:25 p.m.
PT
Location: Ballroom 6 CF - Upper Level - Convention
Center
Poster Presentations
Track: Immunology
Session: Biomarkers, Immune Monitoring and Immune
Assays
Abstract #83: NK cell ADCC assays: Leveraging flow cytometry and
reporter cell lines for enhanced biological relevance and
throughput
Date: Sunday, April
7
Time: 1:30 p.m. - 5:00 p.m.
PT
Section: 3
Track: Molecular/Cellular Biology and Genetics
Session: Cellular Stress Responses 1
Abstract #379: Landscape of HIF-1α expression across 24,186
solid tumors using comprehensive immune
profiling
Date: Sunday, April
7
Time: 1:30 p.m. - 5:00 p.m.
PT
Section: 16
Track: Clinical Research
Session: Circulating Nucleic Acids 1
Abstract #970: Liquid biopsy-informed precision oncology
clinical trial to evaluate the utility of ctDNA
comprehensive genomic profiling
Date:
Sunday, April 7
Time: 1:30 p.m. - 5:00 p.m.
PT
Section: 40
Track: Clinical Research
Session: Predictive Biomarkers 1
Abstract #2496: Molecular characterization of stage III colon
cancer patients with recurrence after adjuvant
chemotherapy
Date: Monday,
April 8
Time: 9:00 a.m. - 12:30 p.m.
PT
Section: 43
Track: Clinical Research
Session: Biomarkers in Clinical Trials
Abstract #3629: Prevalence of claudin18.2 expression in
gastric/gastroesophageal junction adenocarcinoma among patients in
TranStar101 and TranStar102 clinical trials
Date:
Monday, April 8
Time: 1:30 p.m. - 5:00 p.m.
PT
Section: 40
Track: Clinical Research
Session: Biomarkers in Clinical Trials
Abstract #3652: Spatial transcriptomic study of the
tumor microenvironment in HNSCC
Date:
Monday, April 8
Time: 1:30 p.m. - 5:00 p.m.
PT
Section: 40
Track: Experimental and Molecular Therapeutics
Session: Molecular Classification of Tumors for Diagnostics,
Prognostics, and Therapeutic Outcomes
Abstract #4628: Validation of an Automated, Scalable
Comprehensive Genomic Profiling Assay for Hematologic
Malignancies
Date: Tuesday,
April 9
Time: 9:00 a.m. - 12:30 p.m.
PT
Section: 26
Track: Clinical Research
Session: Circulating Nucleic Acids 4
Abstract #5020: Pre-analytical characterization of cell-free DNA
to enable liquid biopsy for solid tumors
Date:
Tuesday, April 9
Time: 9:00 a.m. - 12:30 p.m.
PT
Section: 40
Track: Clinical Research
Session: Circulating Nucleic Acids 4
Abstract #5022: MEDOCC-CrEATE trial: Feasibility of measuring
circulating tumor DNA after surgery to guide adjuvant
chemotherapy in stage II colon cancer patients
Date:
Tuesday, April 9
Time: 9:00 a.m. - 12:30 p.m.
PT
Section: 40
Track: Clinical Research
Session: Circulating Nucleic Acids 4
Abstract #5017: Analytical performance of contrived samples for
validation of liquid biopsy assays
Date: Tuesday, April 9
Time: 9:00 a.m. - 12:30 p.m.
PT
Section: 40
Track: Tumor Biology
Session: Models to Study Immune Cells in the Tumor
Microenvironment
Abstract #4204: Subcutaneous vs. orthotopic tumor models: a
comparative assessment
Date: Tuesday, April 9
Time: 9:00 a.m. - 12:30 p.m.
PT
Section: 10
Track: Tumor Biology
Session: Tumor Evolution Models and Technologies
Abstract #4305: Analysis of tumor heterogeneity in syngeneic
models; CT26.WT colon carcinoma and 4T1-Luc2-1A4 breast carcinoma
in female BALV/cAnNHsd mice
Date: Tuesday, April 9
Time: 9:00 a.m. - 12:30 p.m.
PT
Section: 13
Track: Immunology
Session: Adoptive Cell Therapies 3: CAR-T Cells
Abstract #4002: Investigating CAR-T cell efficacy and activation
in the disseminated NALM6-luc human B-cell acute lymphoblastic
leukemia model
Date: Tuesday,
April 9
Time: 9:00 a.m. – 12:30 p.m. PT
Section: 2
Track: Clinical Research
Session: Predictive Biomarkers 6
Abstract #6443: Enhanced detection of ctDNA molecular
response for immunotherapy treated non-small cell lung cancer
through analyses of cell-free and matched white blood cell
DNA
Date: Tuesday, April
9
Time: 1:30 p.m. - 5:00 p.m.
PT
Section: 44
Track: Clinical Research
Session: Adoptive Cellular Therapy 2
Abstract #6334: Metabolic reprogramming enhances expansion and
potency of CAR T cells
Date: Tuesday, April 9
Time: 1:30 p.m. - 5:00 p.m.
PT
Section: 40
Track: Tumor Biology
Session: Spatial Resolution of the Tumor
Microenvironment
Abstract #5493: Digital spatial profiling of MC38 colon
carcinoma following checkpoint inhibition
Date: Tuesday, April 9
Time: 1:30 p.m. - 5:00 p.m.
PT
Section: 10
Track: Experimental and Molecular Therapeutics
Session: Novel Therapeutics and Preclinical Models
Abstract #6005: Generation of new oncology cell models through
long-term acclimation under hypoxic and hyperbaric culture
conditions
Date: Tuesday,
April 9
Time: 1:30 p.m. - 5:00 p.m.
PT
Section: 28
Track: Clinical Research
Session: Predictive Biomarkers 5
Abstract #6393: The predictive role of TNF-related genes in
patients receiving immune checkpoint inhibitors
Date:
Tuesday, April 9
Time: 1:30 p.m. - 5:00 p.m.
PT
Section: 43
Track: Prevention/Early Detection/Interception,
Population Sciences
Session: Biomarker-Based Screening
Abstract #6079: Comparison of FIT and ctDNA tests for detection
of individuals with colorectal cancer in population-based
screening
Date: Tuesday, April
9
Time: 1:30 p.m. - 5:00 p.m.
PT
Section: 31
Track: Clinical Research; Molecular/Cellular Biology and
Genetics
Session: Immune Checkpoint Inhibitor Therapy
Abstract #7526: Landscape of TIGIT and PD-L1 co-expression in
solid tumors
Date: Wednesday,
April 10
Time: 9:00 a.m. - 12:30 p.m.
PT
Section: 42
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and
comprehensive laboratory services that helps doctors, hospitals,
pharmaceutical companies, researchers and patients make clear and
confident decisions. We provide insights and advance science to
improve health and improve lives through our unparalleled
diagnostics and drug development laboratory capabilities. The
company's more than 67,000 employees serve clients in approximately
100 countries, provided support for 84% of the new drugs and
therapeutic products approved in 2023 by the FDA, and performed
more than 600 million tests for patients around the world. Learn
more about us at www.labcorp.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/labcorp-to-present-diverse-portfolio-of-precision-oncology-research-at-the-annual-meeting-of-the-american-association-for-cancer-research-302105610.html
SOURCE Labcorp